GLPwatch
Tirzepatide: A Double Agonist for Various People Living with Type 2 Diabetes.
Diabetes Ther · 2024
Last updated 2026-05-28Tirzepatide is a once-weekly injectable treatment for type 2 diabetes that works on two hormones, GIP and GLP-1. It has been tested in five large studies involving over 7,000 people with type 2 diabetes, covering different stages of the disease and varying starting conditions.
AI summary of the abstract below.
| Journal | Diabetes Ther, 2024 |
|---|---|
| Citations | 1 |
| Relative citation ratio | 0.10 |
| NIH percentile | 7 |
| Molecules | tirzepatide |
| Conditions studied | Type 2 Diabetes |
Abstract
Tirzepatide is the first ever once-weekly, injectable gastric inhibitory peptide/glucagon-like peptide 1 (GIP/GLP-1) dual agonist approved by the European Medicines Agency for type 2 diabetes. The efficacy and safety of tirzepatide have been evaluated in five global, randomized, double-blind or open-label, phase 3 studies which enrolled over 7000 people living with type 2 diabetes, across various stages of disease and with different characteristics at baseline. In this short commentary we report the salient data of the most recent trials on tirzepatide and GLP-1 receptor agonists from a clinical point of view, with the aim of highlighting similarities and mutual differences.
Verbatim abstract via PubMed 39085745 ↗
Related research
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.